Onyx Pharms Amgen Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ONYX PHARMS AMGEN, and what generic alternatives to ONYX PHARMS AMGEN drugs are available?
ONYX PHARMS AMGEN has one approved drug.
There are eleven US patents protecting ONYX PHARMS AMGEN drugs.
There are one hundred and ninety-one patent family members on ONYX PHARMS AMGEN drugs in forty-two countries and eighteen supplementary protection certificates in sixteen countries.
Summary for Onyx Pharms Amgen
| International Patents: | 191 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Onyx Pharms Amgen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 7,737,112 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | AP | RX | Yes | Yes | 9,493,582 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 9,493,582 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 8,207,126 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ONYX PHARMS AMGEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 10 mg/vial | ➤ Subscribe | 2018-11-28 |
| ➤ Subscribe | For Injection | 60 mg/vial | ➤ Subscribe | 2016-07-20 |
International Patents for Onyx Pharms Amgen Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1152536 | ⤷ Subscribe |
| Japan | 2014141456 | ⤷ Subscribe |
| Japan | 2007537265 | ⤷ Subscribe |
| South Korea | 101299821 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Onyx Pharms Amgen Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1781688 | C 2016 014 | Romania | ⤷ Subscribe | PRODUCT NAME: CARFILZOMIB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1060; DATE OF NATIONAL AUTHORISATION: 20151119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1060; DATE OF FIRST AUTHORISATION IN EEA: 20151119 |
| 1781688 | 132016000047656 | Italy | ⤷ Subscribe | PRODUCT NAME: CARFILZOMIB OPZIONALMENTE IN FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE(KYPROLIS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1060, 20151123 |
| 1781688 | CR 2016 00014 | Denmark | ⤷ Subscribe | PRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE HERAF; REG. NO/DATE: EU/1/15/1060 20151123 |
| 1781688 | PA2016010,C1781688 | Lithuania | ⤷ Subscribe | PRODUCT NAME: KARFILZOMIBAS; REGISTRATION NO/DATE: EU/1/15/1060 20151119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
